Antibody light-chain-restricted recognition of the site of immune pressure in the RV144 HIV-1 vaccine trial is phylogenetically conserved

Immunity

Volumn 41, Issue 6, 2014, Pages 909-918

  Wiehe, Kevin ^a   Easterhoff, David ^a   Luo, Kan ^a   Nicely, Nathan I ^a   Bradley, Todd ^a   Jaeger, Frederick H ^a   Dennison, S Moses ^a   Zhang, Ruijun ^a   Lloyd, Krissey E ^a   Stolarchuk, Christina ^a   Parks, Robert ^a   Sutherland, Laura L ^a   Scearce, Richard M ^a   Morris, Lynn ^b   Kaewkungwal, Jaranit ^c   Nitayaphan, Sorachai ^d   Pitisuttithum, Punnee ^c   Rerks Ngarm, Supachai ^e   Sinangil, Faruk ^f   Phogat, Sanjay ^g   Michael, Nelson L ^h   Kim, Jerome H ^h   Kelsoe, Garnett ^a   Montefiori, David C ^a   Tomaras, Georgia D ^a   Bonsignori, Mattia ^a   Santra, Sampa ⁱ   Kepler, Thomas B ^j   Alam, S Munir ^a   Moody, M Anthony ^a   Liao, Hua Xin ^a   Haynes, Barton F ^a   more..

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF KWAZULU NATAL   (South Africa)

^c MAHIDOL UNIVERSITY   (Thailand)

^d ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

^e MINISTRY OF PUBLIC HEALTH   (Thailand)

^f SANOFI PASTEUR   (France)

^g Global Solutions for Infectious Diseases   (United States)

^h WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

ⁱ HARVARD MEDICAL SCHOOL   (United States)

^j BOSTON UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GLYCOPROTEIN GP 120; GP120 PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN LIGHT CHAIN; PROTEIN BINDING; VIRUS ANTIBODY;

AMINO ACID SEQUENCE; ANIMAL; ANTIBODY AFFINITY; B LYMPHOCYTE; CELL CULTURE; CLINICAL TRIAL (TOPIC); EPITOPE MAPPING; GENETICS; HIV INFECTIONS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; METABOLISM; MOLECULAR GENETICS; MUTATION; NUCLEOTIDE SEQUENCE; PHYLOGENY; PROTEIN ENGINEERING; RHESUS MONKEY;

AIDS VACCINES; AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, VIRAL; ANTIBODY AFFINITY; B-LYMPHOCYTES; CELLS, CULTURED; CLINICAL TRIALS AS TOPIC; CONSERVED SEQUENCE; EPITOPE MAPPING; EPITOPES, B-LYMPHOCYTE; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; MACACA MULATTA; MOLECULAR SEQUENCE DATA; MUTATION; PHYLOGENY; PROTEIN BINDING; PROTEIN ENGINEERING;

EID: 84918548024     PISSN: 10747613     EISSN: 10974180     Source Type: Journal    
DOI: 10.1016/j.immuni.2014.11.014     Document Type: Article

References (44)

1. Adams P.D., Afonine P.V., Bunkóczi G., Chen V.B., Davis I.W., Echols N., Headd J.J., Hung L.W., Kapral G.J., Grosse-Kunstleve R.W., et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 2010, 66:213-221.
2. Alam S.M., McAdams M., Boren D., Rak M., Scearce R.M., Gao F., Camacho Z.T., Gewirth D., Kelsoe G., Chen P., Haynes B.F. The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopes. J.Immunol. 2007, 178:4424-4435.
3. Alam S.M., Liao H.X., Dennison S.M., Jaeger F., Parks R., Anasti K., Foulger A., Donathan M., Lucas J., Verkoczy L., et al. Differential reactivity of germ line allelic variants of a broadly neutralizing HIV-1 antibody to a gp41 fusion intermediate conformation. J.Virol. 2011, 85:11725-11731.
4. Bonsignori M., Pollara J., Moody M.A., Alpert M.D., Chen X., Hwang K.K., Gilbert P.B., Huang Y., Gurley T.C., Kozink D.M., et al. Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. J.Virol. 2012, 86:11521-11532.
5. Briney B.S., Willis J.R., Crowe J.E. Human peripheral blood antibodies with long HCDR3s are established primarily at original recombination using a limited subset of germline genes. PLoS ONE 2012, 7:e36750.
6. Compton A.A., Emerman M. Convergence and divergence in the evolution of the APOBEC3G-Vif interaction reveal ancient origins of simian immunodeficiency viruses. PLoS Pathog. 2013, 9:e1003135.
7. Dal Porto J.M., Haberman A.M., Shlomchik M.J., Kelsoe G. Antigen drives very low affinity B cells to become plasmacytes and enter germinal centers. J.Immunol. 1998, 161:5373-5381.
8. de Wildt R.M., Hoet R.M., van Venrooij W.J., Tomlinson I.M., Winter G. Analysis of heavy and light chain pairings indicates that receptor editing shapes the human antibody repertoire. J.Mol. Biol. 1999, 285:895-901.
9. Emsley P., Lohkamp B., Scott W.G., Cowtan K. Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 2010, 66:486-501.
10. Frippiat J.P., Lefranc M.P. Genomic organisation of 34 kb of the human immunoglobulin lambda locus (IGLV): restriction map and sequences of new V lambda III genes. Mol. Immunol. 1994, 31:657-670.
11. Gao F., Bonsignori M., Liao H.X., Kumar A., Xia S.M., Lu X., Cai F., Hwang K.K., Song H., Zhou T., et al. Cooperation of B cell lineages in induction of HIV-1-broadly neutralizing antibodies. Cell 2014, 158:481-491.
12. Gibbs R.A., Rogers J., Katze M.G., Bumgarner R., Weinstock G.M., Mardis E.R., Remington K.A., Strausberg R.L., Venter J.C., Wilson R.K., et al. Evolutionary and biomedical insights from the rhesus macaque genome. Science 2007, 316:222-234. Rhesus Macaque Genome Sequencing and Analysis Consortium.
13. Gnanakaran S., Daniels M.G., Bhattacharya T., Lapedes A.S., Sethi A., Li M., Tang H., Greene K., Gao H., Haynes B.F., et al. Genetic signatures in the envelope glycoproteins of HIV-1 that associate with broadly neutralizing antibodies. PLoS Comput. Biol. 2010, 6:e1000955.
14. Gorny M.K., Moore J.P., Conley A.J., Karwowska S., Sodroski J., Williams C., Burda S., Boots L.J., Zolla-Pazner S. Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1. J.Virol. 1994, 68:8312-8320.
15. Gorny M.K., Pan R., Williams C., Wang X.H., Volsky B., O'Neal T., Spurrier B., Sampson J.M., Li L., Seaman M.S., et al. Functional and immunochemical cross-reactivity of V2-specific monoclonal antibodies from HIV-1-infected individuals. Virology 2012, 427:198-207.
16. Haynes B.F., Gilbert P.B., McElrath M.J., Zolla-Pazner S., Tomaras G.D., Alam S.M., Evans D.T., Montefiori D.C., Karnasuta C., Sutthent R., et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N.Engl. J. Med. 2012, 366:1275-1286.
17. Haynes B.F., Kelsoe G., Harrison S.C., Kepler T.B. B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat. Biotechnol. 2012, 30:423-433.
18. Jayaram N., Bhowmick P., Martin A.C. Germline VH/VL pairing in antibodies. Protein Eng. Des. Sel. 2012, 25:523-529.
19. Kepler T.B. Reconstructing a B-cell clonal lineage. I. Statistical inference of unobserved ancestors. F1000Res. 2013, 2:103.
20. Kwong P.D., Mascola J.R. Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. Immunity 2012, 37:412-425.
21. Lefranc M.P. IMGT, the international ImMunoGeneTics database. Nucleic Acids Res. 2001, 29:207-209.
22. Liao H.X., Sutherland L.L., Xia S.M., Brock M.E., Scearce R.M., Vanleeuwen S., Alam S.M., McAdams M., Weaver E.A., Camacho Z., et al. A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses. Virology 2006, 353:268-282.
23. Liao H.X., Levesque M.C., Nagel A., Dixon A., Zhang R., Walter E., Parks R., Whitesides J., Marshall D.J., Hwang K.K., et al. High-throughput isolation of immunoglobulin genes from single human B cells and expression as monoclonal antibodies. J.Virol. Methods 2009, 158:171-179.
24. Liao H.X., Chen X., Munshaw S., Zhang R., Marshall D.J., Vandergrift N., Whitesides J.F., Lu X., Yu J.S., Hwang K.K., et al. Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated. J.Exp. Med. 2011, 208:2237-2249.
25. Liao H.X., Bonsignori M., Alam S.M., McLellan J.S., Tomaras G.D., Moody M.A., Kozink D.M., Hwang K.K., Chen X., Tsao C.Y., et al. Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity 2013, 38:176-186.
26. Lovell S.C., Davis I.W., Arendall W.B., de Bakker P.I., Word J.M., Prisant M.G., Richardson J.S., Richardson D.C. Structure validation by Calpha geometry: phi,psi and Cbeta deviation. Proteins 2003, 50:437-450.
27. Matthews B.W. Solvent content of protein crystals. J.Mol. Biol. 1968, 33:491-497.
28. Mayr L.M., Cohen S., Spurrier B., Kong X.P., Zolla-Pazner S. Epitope mapping of conformational V2-specific anti-HIV human monoclonal antibodies reveals an immunodominant site in V2. PLoS ONE 2013, 8:e70859.
29. + T-lymphoblastoid cell assay system. PLoS ONE 2013, 8:e77756.
30. Morris L., Chen X., Alam M., Tomaras G., Zhang R., Marshall D.J., Chen B., Parks R., Foulger A., Jaeger F., et al. Isolation of a human anti-HIV gp41 membrane proximal region neutralizing antibody by antigen-specific single B cell sorting. PLoS ONE 2011, 6:e23532.
31. Munshaw S., Kepler T.B. SoDA2: a Hidden Markov Model approach for identification of immunoglobulin rearrangements. Bioinformatics 2010, 26:867-872.
32. Nicely N.I., Dennison S.M., Spicer L., Scearce R.M., Kelsoe G., Ueda Y., Chen H., Liao H.X., Alam S.M., Haynes B.F. Crystal structure of a non-neutralizing antibody to the HIV-1 gp41 membrane-proximal external region. Nat. Struct. Mol. Biol. 2010, 17:1492-1494.
33. Otwinowski Z., Minor W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 1997, 276:307-326.
34. Perelman P., Johnson W.E., Roos C., Seuánez H.N., Horvath J.E., Moreira M.A., Kessing B., Pontius J., Roelke M., Rumpler Y., et al. A molecular phylogeny of living primates. PLoS Genet. 2011, 7:e1001342.
35. Rerks-Ngarm S., Pitisuttithum P., Nitayaphan S., Kaewkungwal J., Chiu J., Paris R., Premsri N., Namwat C., de Souza M., Adams E., et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N.Engl. J. Med. 2009, 361:2209-2220. MOPH-TAVEG Investigators.
36. Rolland M., Edlefsen P.T., Larsen B.B., Tovanabutra S., Sanders-Buell E., Hertz T., deCamp A.C., Carrico C., Menis S., Magaret C.A., et al. Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature 2012, 490:417-420.
37. Sarzotti-Kelsoe M., Bailer R.T., Turk E., Lin C.L., Bilska M., Greene K.M., Gao H., Todd C.A., Ozaki D.A., Seaman M.S., et al. Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1. J.Immunol. Methods 2014, 409:131-146.
38. Schmidt A.G., Xu H., Khan A.R., O'Donnell T., Khurana S., King L.R., Manischewitz J., Golding H., Suphaphiphat P., Carfi A., et al. Preconfiguration of the antigen-binding site during affinity maturation of a broadly neutralizing influenza virus antibody. Proc. Natl. Acad. Sci. USA 2013, 110:264-269.
39. Shih T.A., Meffre E., Roederer M., Nussenzweig M.C. Role of BCR affinity in Tcell dependent antibody responses invivo. Nat. Immunol. 2002, 3:570-575.
40. Stone M.J., Chuang S., Hou X., Shoham M., Zhu J.Z. Tyrosine sulfation: an increasingly recognised post-translational modification of secreted proteins. New Biotechnol. 2009, 25:299-317.
41. Terwilliger T.C., Grosse-Kunstleve R.W., Afonine P.V., Moriarty N.W., Zwart P.H., Hung L.W., Read R.J., Adams P.D. Iterative model building, structure refinement and density modification with the PHENIX AutoBuild wizard. Acta Crystallogr. D Biol. Crystallogr. 2008, 64:61-69.
42. West A.P., Diskin R., Nussenzweig M.C., Bjorkman P.J. Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120. Proc. Natl. Acad. Sci. USA 2012, 109:E2083-E2090.
43. Zhou T., Zhu J., Wu X., Moquin S., Zhang B., Acharya P., Georgiev I.S., Altae-Tran H.R., Chuang G.Y., Joyce M.G., et al. Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies. Immunity 2013, 39:245-258. NISC Comparative Sequencing Program.
44. Zwick M.B., Labrijn A.F., Wang M., Spenlehauer C., Saphire E.O., Binley J.M., Moore J.P., Stiegler G., Katinger H., Burton D.R., Parren P.W. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J.Virol. 2001, 75:10892-10905.